Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV
Clinical trial NCT05107778 · COMPLETED
Trial details
- NCT number
- NCT05107778
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-10
- Primary completion
- 2023-11-14
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.